BMND07

**BMND07** is an investigational proprietary psychedelic small-molecule combination candidate developed by Biomind Labs for **major depressive disorder**. Biomind Labs has described BMND07 as a DMT-based combination candidate and reported preclinical in vivo toxicology findings of low acute oral toxicity and no mutagenic effects in animals at the tested doses. A subsequent corporate update identified BMND07 work as pharmaceutical-grade 5-methoxy-N,N-dimethyltryptamine free-base API synthesis, while the current company pipeline lists the program for major depressive disorder at the evaluation stage. The complete active-ingredient composition and intended clinical formulation have not been publicly disclosed. ([businesswire.com](https://www.businesswire.com/news/home/20220303005501/en/Biomind-Labs-Announces-Positive-Results-on-in-vivo-Studies-for-Its-Proprietary-Drug-Candidate-BMND07))